Literature DB >> 10895045

Metabolic consequences of growth hormone treatment in paediatric practice.

P Saenger1.   

Abstract

No metabolic side-effects of clinical significance have been reported during a 5-year study of growth hormone (GH) therapy in children with GH deficiency, Turner syndrome, idiopathic short stature or chronic renal insufficiency. In particular, insulin levels increase but remain within the normal range, as do glucose and haemoglobin A(1c). A recent study showed that the effects of growth on insulin sensitivity in prepubertal children with idiopathic short stature represent the changes in carbohydrate tolerance observed during normal adolescence. Thus, GH treatment may lead to prolongation of the physiological state of insulin resistance observed in normal puberty. Insulin levels during the fasting state and 2 h after a standard glucose load showed no further rise after the first 3 years of continuous GH therapy. The hyperinsulinaemia observed during GH therapy may, therefore, amplify the anabolic effects of insulin on protein metabolism during puberty. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10895045     DOI: 10.1159/000053207

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  9 in total

Review 1.  The use of somatropin (recombinant growth hormone) in children of short stature.

Authors:  Ameeta Mehta; Peter C Hindmarsh
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

2.  Reduction in insulin sensitivity and inadequate β-cell capacity to counteract the increase in insulin resistance in children with idiopathic growth hormone deficiency during 12 months of growth hormone treatment.

Authors:  A Ciresi; M C Amato; C Giordano
Journal:  J Endocrinol Invest       Date:  2014-10-02       Impact factor: 4.256

Review 3.  Insulin Resistance of Puberty.

Authors:  Megan M Kelsey; Philip S Zeitler
Journal:  Curr Diab Rep       Date:  2016-07       Impact factor: 4.810

Review 4.  Growth hormone treatment in children: review of safety and efficacy.

Authors:  Mark Harris; Paul L Hofman; Wayne S Cutfield
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

5.  Lean polycystic ovary syndrome (PCOS): an evidence-based practical approach.

Authors:  Sehar Toosy; Ravinder Sodi; Joseph M Pappachan
Journal:  J Diabetes Metab Disord       Date:  2018-11-13

6.  The metabolic outcomes of growth hormone treatment in children are gender specific.

Authors:  Alessandro Ciresi; Stefano Radellini; Valentina Guarnotta; Maria Grazia Mineo; Carla Giordano
Journal:  Endocr Connect       Date:  2018-06-20       Impact factor: 3.335

Review 7.  Glucose Metabolism in Children With Growth Hormone Deficiency.

Authors:  Alessandro Ciresi; Carla Giordano
Journal:  Front Endocrinol (Lausanne)       Date:  2018-06-11       Impact factor: 5.555

8.  Growth Hormone Treatment and Papilledema: A Prospective Pilot Study

Authors:  Nieves Martín-Begué; Eduard Mogas; Charlotte Wolley Dod; Silvia Alarcón; María Clemente; Ariadna Campos-Martorell; Ana Fábregas; Diego Yeste
Journal:  J Clin Res Pediatr Endocrinol       Date:  2020-10-02

9.  Visceral fat thickness and its associations with pubertal and metabolic parameters among girls with precocious puberty.

Authors:  Dong Wook Kim; Junghwan Suh; Ah Reum Kwon; Hyun Wook Chae; Choon Sik Yoon; Ho-Seong Kim; Duk Hee Kim
Journal:  Ann Pediatr Endocrinol Metab       Date:  2018-06-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.